Journal Article
. 2016 Apr;27(6).
doi: 10.1007/s10552-016-0743-4.

Underutilization of gene expression profiling for early-stage breast cancer in California

Rosemary D Cress 1 Yingjia S Chen 2 Cyllene R Morris 3 Helen Chew 4 Kenneth W Kizer 3 
Affiliations
  • PMID: 27097910
  •     23 References
  •     7 citations

Abstract

Purpose: To describe the utilization of gene expression profiling (GEP) among California breast cancer patients, identify predictors of use of GEP, and evaluate how utilization of GEP influenced treatment of early-stage breast cancer.

Methods: All women diagnosed with hormone-receptor-positive, node-negative breast cancer reported to the California Cancer Registry between January 2008 and December 2010 were linked to Oncotype DX (ODX) assay results.

Results: Overall, 26.7 % of 23,789 eligible patients underwent the assay during the study period. Women age 65 or older were much less likely than women under age 50 to be tested (15.1 vs. 41.4 %, p < 0.001). Black women were slightly less likely and Asian women were slightly more likely than non-Hispanic white women to undergo GEP with the ODX assay (22.2 and 28.9 vs. 26.9 %, respectively, p < 0.001). Patients residing in low SES census tracts had the lowest use of the test (8.9 %), with the proportion increasing with higher SES category. Women with Medicaid health insurance were less likely than other women to be tested (17.7 vs. 27.5 %, p < 0.001). Receipt of adjuvant chemotherapy (ACT) was associated with the ODX recurrence score, although only 63 % of patients whose recurrence scores indicated a high benefit received ACT. Of patients not tested, 15 % received ACT.

Conclusions: Nearly three-fourths of eligible breast cancer patients in California during the 3-year period 2008 through 2010 did not undergo GEP. As a result, it is likely that many women unnecessarily received ACT and suffered associated morbidity. In addition, some high-risk women who would have benefited most from ACT were not identified.

Keywords: Breast cancer; Cancer registry; Chemotherapy; Gene expression profiling; Genomics.

Utilization of Oncotype DX in an Inner City Population: Race or Place?
Amber A Guth, Susan Fineberg, +2 authors, Nina A Bickell.
Int J Breast Cancer, 2014 Jan 24; 2013. PMID: 24455283    Free PMC article.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance.
Joan L Warren, Eboneé N Butler, +4 authors, Linda C Harlan.
J Clin Oncol, 2014 Dec 24; 33(4). PMID: 25534387    Free PMC article.
Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
Jennifer J Griggs, Sarah T Hawley, +8 authors, Steven J Katz.
J Clin Oncol, 2012 Aug 08; 30(25). PMID: 22869890    Free PMC article.
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler.
J Clin Oncol, 2015 Nov 26; 34(2). PMID: 26598755    Free PMC article.
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L Potosky, Suzanne C O'Neill, +8 authors, Marc D Schwartz.
Cancer, 2015 Aug 21; 121(22). PMID: 26291519    Free PMC article.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2016 Mar 10; 14(3). PMID: 26957618
Highly Cited.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.
K Yost, C Perkins, +2 authors, W Wright.
Cancer Causes Control, 2001 Sep 20; 12(8). PMID: 11562110
Highly Cited.
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +2 authors, Lesley H Curtis.
JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
Impact of oncotype DX recurrence score in the management of breast cancer cases.
Michaela T Nguyen, Alexander Stessin, +5 authors, Sandra J Shin.
Clin Breast Cancer, 2014 Feb 04; 14(3). PMID: 24486121
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Comparison of SEER Treatment Data With Medicare Claims.
Anne-Michelle Noone, Jennifer L Lund, +4 authors, Joan L Warren.
Med Care, 2014 Mar 19; 54(9). PMID: 24638121    Free PMC article.
Highly Cited.
Cancer statistics, 2015.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2015 Jan 07; 65(1). PMID: 25559415
Highly Cited.
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Gary H Lyman, Leon E Cosler, Nicole M Kuderer, John Hornberger.
Cancer, 2007 Feb 22; 109(6). PMID: 17311307
Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
Lindsey Enewold, Ann M Geiger, JoAnne Zujewski, Linda C Harlan.
Breast Cancer Res Treat, 2015 Apr 11; 151(1). PMID: 25859924
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.
Jennifer S Haas, Su-Ying Liang, +3 authors, Kathryn A Phillips.
Breast Cancer Res Treat, 2011 Jun 18; 130(2). PMID: 21681446    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Progress in the clinical detection of heterogeneity in breast cancer.
Jun-Long Song, Chuang Chen, Jing-Ping Yuan, Sheng-Rong Sun.
Cancer Med, 2016 Oct 25; 5(12). PMID: 27774765    Free PMC article.
Review.
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
Breast Cancer Res, 2017 Apr 01; 19(1). PMID: 28359319    Free PMC article.
Critical Lessons From High-Value Oncology Practices.
Douglas W Blayney, Melora K Simon, +4 authors, Arnold Milstein.
JAMA Oncol, 2017 Nov 18; 4(2). PMID: 29145584    Free PMC article.
Disparities in quality of cancer care: The role of health insurance and population demographics.
Arti Parikh-Patel, Cyllene R Morris, Kenneth W Kizer.
Medicine (Baltimore), 2018 Feb 03; 96(50). PMID: 29390313    Free PMC article.
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Lindsay J Collin, Ming Yan, +8 authors, Lauren E McCullough.
NPJ Breast Cancer, 2019 Oct 05; 5. PMID: 31583272    Free PMC article.
First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting.
Frances B Maguire, Cyllene R Morris, +5 authors, Kenneth W Kizer.
JNCI Cancer Spectr, 2020 Apr 25; 3(3). PMID: 32328551    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.